SEC filings and other documents

Q1 2026 saw revenue growth, margin expansion, and key reimbursement milestones achieved.

2025 saw revenue decline but strong margin gains and a 2026 outlook for renewed growth.

Q3 revenue up 21% year-over-year, with record flow cell sales and improved gross margin.

Consumables and software drive growth as OGM adoption expands in cytogenetic labs.

Optical genome mapping drives digital pathology transformation, fueling growth and profitability.

Q2 2025 saw higher margins and consumables growth, with full-year guidance reaffirmed.

OGM adoption accelerates with improved margins, reimbursement, and global clinical traction.

All proposals, including director elections and share issuance, were approved by stockholders.

Gross margin surged to 46% as cost cuts offset a 26% revenue drop in Q1 2025.

Share issuance and reverse stock split proposals both approved by stockholders.

Q4 revenue down 24% but gross margin up; 2025 revenue guided at $29M–$32M.

Severe losses, negative cash flow, and urgent funding needs threaten Bionano's ongoing viability.